Discover and read the best of Twitter Threads about #LBCT
Most recents (10)
Using Pulsed field ablation rather than thermal modes through irreversible electroporation (IRE).
#ACC23 #CardioNerds
#ACC23 #CardioNerds
🔺 Pulsed field ablation resulted in 79.7% (paroxysmal) and 80.8% (persistent) clinical success. 🫀
#ACC23 #CardioNerds
#ACC23 #CardioNerds
TRANSFORM-HF
What do we really know about efficacy of furosemide vs torsemide?
I am sure @robmentz and team have something to say about this 👊🏾
pubmed.ncbi.nlm.nih.gov/33714745/
#AHA #LBCT @AHAScience @noshreza
What do we really know about efficacy of furosemide vs torsemide?
I am sure @robmentz and team have something to say about this 👊🏾
pubmed.ncbi.nlm.nih.gov/33714745/
#AHA #LBCT @AHAScience @noshreza
Chlorthalidone versus HCTZ - pragmatic emr study by @Areefishani et al. After #SPRINTTrial I use chlorthalidone. What’s the evidence?
pubmed.ncbi.nlm.nih.gov/35390512/
#AHA #LBCT @AHAScience @noshreza
pubmed.ncbi.nlm.nih.gov/35390512/
#AHA #LBCT @AHAScience @noshreza
PPAR-alpha (e.g., fenofibrate, permafibrate) - Are triglycerides as a target out for CV event reduction, or just this mechanism?
pubmed.ncbi.nlm.nih.gov/30342298/ @APradhanBrigham to present 👊🏾
#AHA #LBCT @AHAScience @noshreza
pubmed.ncbi.nlm.nih.gov/30342298/ @APradhanBrigham to present 👊🏾
#AHA #LBCT @AHAScience @noshreza
Hey #ACC22 presenters, especially late breaking studies of consequence. If you don't have simultaneous peer-reviewed pub, consider #preprint what you presented so it's archived & accessible. Let’s make it normative. @medrxivpreprint @yaleHFdoc #LBCT @EricTopol @CMichaelGibson
@medrxivpreprint @yaleHFdoc @EricTopol @CMichaelGibson For all #ACC22 presenters, preprinting is easy; we accept scientific studies, screen rapidly, post quickly. Non-profit. It is of the community-available throughout the world, understood as pre-peer reviewed, and citable. Almost all reputable journals are fine with it, incl @NEJM.
@medrxivpreprint @yaleHFdoc @EricTopol @CMichaelGibson @NEJM In the pandemic @medrxivpreprint stimulated discussions about research in progress, & many examples of advancing research. Cardiology has not yet fully embraced it, yet is this work any less important? All fields should accelerate public scientific communication & #openscience.
1) Welcome to an #accredited #tweetorial on a unique emerging (in Ph3 now) option for specifically reversing the #antiplatelet effects of #ticagrelor: it's #bentracimab. Expert faculty is antithrombotic agent reversal guru @md_pollack of @UMMCnews, working to create #AHealthierMS
2) This program is intended for #healthcare professionals and is supported by an educational grant from PhaseBio Pharmaceuticals. Faculty disclosures are listed at cardiometabolic-ce.com/disclosures/, and prior programs are available for 🆓CE/#CME credit at cardiometabolic-ce.com.
3) It is an unfortunate fact of life that one cannot prescribe #anticoagulant or #antiplatelet (together, #antithrombotic) therapy without increasing a patient's #bleedingrisk. That is why it should be an individualized risk:benefit decision, ideally . . .
#mSToPs Study presented at #AHA20 #LBCT @SteveSteinhubl @EricTopol
💫Lifetime risk of Afib ⬆️ (.40%)
💥Risk of #Afib is stroke but also Heart Failure and CV Mortality is even ⬆️⬆️
🥅 was to assess ECG patch in diagnosis of Afib & improve outcomes
💫Lifetime risk of Afib ⬆️ (.40%)
💥Risk of #Afib is stroke but also Heart Failure and CV Mortality is even ⬆️⬆️
🥅 was to assess ECG patch in diagnosis of Afib & improve outcomes
#ESCCongress #LoDoCo2 Results #LBCT
Colchicine also a winner of @escardio 2020
This study was building on COLCOT results in secondary prevention in patients w/ chronic CAD
🔺5522 patients enrolled
🔺Randomized to Colchicine 0.5 mg vs Placebo
🔺Excluded advanced CKD, HF, valve ds
Colchicine also a winner of @escardio 2020
This study was building on COLCOT results in secondary prevention in patients w/ chronic CAD
🔺5522 patients enrolled
🔺Randomized to Colchicine 0.5 mg vs Placebo
🔺Excluded advanced CKD, HF, valve ds
Characteristics of #LoDoCo2 #ESCCongress
🔺90% of patients tolerated medication
🔺Mostly men (84%)
🔺Most had prior revascularization
🔺 Most well treated
🔺90% of patients tolerated medication
🔺Mostly men (84%)
🔺Most had prior revascularization
🔺 Most well treated
Results of #LoDoCo2 show dramatic effect of colchicine in these patients with chronic CAD
♥️30% reduction in treatment arm for Primary Outcome
♥️28% ⤵️ in MACE
♥️subgroup analysis shown
#ESCCongress #residualrisk #colchicine #inflammation
♥️30% reduction in treatment arm for Primary Outcome
♥️28% ⤵️ in MACE
♥️subgroup analysis shown
#ESCCongress #residualrisk #colchicine #inflammation
Looking forward to sharing results #BlueSyncStudy (First pacemaker to use the patient's smart device for remote monitoring) tomorrow at #LBCT session #HRS2020Science @HRSonline The session is available online tomorrow 5/9/2020 at 11:00 AM EST heartrhythm365.org/Public/Catalog…
All the gratitude to colleagues on the steering committee, investigators/teams in US, UK, France, Italy, the @Medtronic team and most importantly to all our patients who pariticpated in the #BlueSyncStudy #HRS2020Science @leftbundle @StevenZweibel @drsuneet @Allred_J @nshaik14
#ACC19 #LBCT
@PCRonline
1PANACHE: Safety:Efficacy of Neladenoson Bialanate, Partial Adenosine A1 Receptor Agonist, in CHF & Preserved EF: PANACHE RCT
2PIONEER-HF: Initiation of Angiotensin-Neprilysin Inhibition after Acute Decomp CHF: Open-Label Extension of
PIONEER-HF Trial
@PCRonline
1PANACHE: Safety:Efficacy of Neladenoson Bialanate, Partial Adenosine A1 Receptor Agonist, in CHF & Preserved EF: PANACHE RCT
2PIONEER-HF: Initiation of Angiotensin-Neprilysin Inhibition after Acute Decomp CHF: Open-Label Extension of
PIONEER-HF Trial
3 Hopeful Heart Trial: Blended Collaborative Care for Treating ❤️Failure & Comorbid Depression: 12-Month Outcomes
4 CODIACS-QoL: Randomized Trial of Depression Screening After ACS: Comparison of Depression Identification After ACS-QOL & Cost Effectiveness
4 CODIACS-QoL: Randomized Trial of Depression Screening After ACS: Comparison of Depression Identification After ACS-QOL & Cost Effectiveness
Proud to have led this #clusterRCT, presented @ESCCardio's #LBCT session & published today in @JAMA_current. Among 2495 adults (50% women) hospitalized for #HF, a transitional care model implemented in our publiclyfunded system did not ⬇️time to comp readmission/ED visit/death.
There was a significant improvement in the patient-reported outcomes of #discharge-preparedness, #qualityofcaretransition, and #QOL. However, there was no improvement in #QALY. The #PROs were not adjusted for multiplicity, but we will do post-hoc exploratory analysis.
